New Developments in Antirheumatic Therapy

  • K. D. Rainsford
  • G. P. Velo

Part of the Inflammation and Drug Therapy Series book series (IDTH, volume 3)

Table of contents

  1. Front Matter
    Pages i-viii
  2. P. Nash, B. L. Hazleman
    Pages 1-28
  3. C. W. Denko
    Pages 29-35
  4. I. M. Hunneyball, M. E. J. Billingham, K. D. Rainsford
    Pages 93-131
  5. Lisa A. Marshall, Joseph Chang
    Pages 133-151
  6. Henry J. Lee, Ann S. Heiman, Irach B. Taraporewala
    Pages 153-186
  7. Dennis V. Parke, Andrew M. Symons, Ann L. Parke
    Pages 187-206
  8. Davin R. Haynes, Michael W. Whitehouse
    Pages 207-233
  9. Michael C. Powanda, Elizabeth D. Moyer
    Pages 255-276
  10. Ivan G. Otterness, Marcia L. Bliven
    Pages 277-304
  11. F. M. Veronese, A. Conforti, G. P. Velo
    Pages 305-314
  12. Back Matter
    Pages 315-328

About this book

Introduction

At present we may be at the cross-roads in the therapeutic approaches we have for the treatment of the 100 or more rheumatic conditions. This is be­ cause we now recognise that although some advances have been made with the development of a large range of non-steroidal and steroidal drugs during the past two decades or so, we now recognise that many, if not all, of these have rather limited effects on many of the disease processes which underlie the manifestations of the various rheumatic states. Advances in molecular bi- 010gy in the past 5-10 years have enabled these tools to be applied extensive­ ly for developing further our understanding of the rheumatic disease processes. In some cases these molecular tools (e. g. ,),-interferon, interleukin- 2, T-cell antibodies) have been directly employed as therapies themselves. While the outcome from trials with such agents in rheumatoid arthritis in particular has not been as would have been hoped, these results as with cy­ closporin A and low-dose methotrexate in the therapy of rheumatoid arth­ ritis have given us important indications for the approach employing what are generally described as "immunomodulators" to control this disease. But this may not be the same type of approach which is desirable for all types of rheumatic conditions. Indeed, even the way which the present range of drugs and other therapies are applied may not be the most effective and safe means of treating different types of arthritic conditions.

Keywords

Arthritis drug drug development inflammation osteoarthritis research rheumatoid arthritis toxicity

Editors and affiliations

  • K. D. Rainsford
    • 1
  • G. P. Velo
    • 2
  1. 1.Department of Biomedical SciencesMcMaster University Faculty of Health SciencesHamiltonCanada
  2. 2.Institute of PharmacologyUniversity of VeronaItaly

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-009-1253-3
  • Copyright Information Springer Science+Business Media B.V. 1989
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-94-010-7056-0
  • Online ISBN 978-94-009-1253-3
  • Series Print ISSN 0923-9405
  • About this book
Industry Sectors
Chemical Manufacturing
Biotechnology
Consumer Packaged Goods
Pharma